Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
25.14
-0.24 (-0.95%)
Dec 20, 2024, 4:00 PM EST - Market closed
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for CLDX stock have an average target of 64.83, with a low estimate of 37 and a high estimate of 90. The average target predicts an increase of 157.88% from the current stock price of 25.14.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CLDX stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Buy | 3 | 3 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +218.22% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +218.22% | Dec 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +218.22% | Nov 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +218.22% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +218.22% | Oct 28, 2024 |
Financial Forecast
Revenue This Year
6.33M
from 6.88M
Decreased by -7.99%
Revenue Next Year
3.72M
from 6.33M
Decreased by -41.29%
EPS This Year
-2.47
from -2.92
EPS Next Year
-3.30
from -2.47
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 9.8M | 12.6M | 11.8M | |||
| Avg | 6.3M | 3.7M | 3.8M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 41.9% | 99.0% | 216.3% | |||
| Avg | -8.0% | -41.3% | 3.3% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.26 | -2.58 | -2.32 | |||
| Avg | -2.47 | -3.30 | -3.85 | |||
| Low | -2.57 | -3.59 | -4.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.